Genmab — Februar 2026
-
Novartis - Q4 2025 Kesimpta (USD 1 228 million, +27% cc) sales grew across all regions driven by increased demand and strong access FY 2025 4 426 https://www.novartis.com/sites/novartis_com/files/q4-2025-media-release-en.pdf https://www.novartis.com/sites/novartis_com/files/q4-2025-investor-presentation.pdf
-
Fitch Assigns Genmab A/S Final 'BB' Rating; Outlook Stable https://www.fitchratings.com/research/corporate-finance/fitch-assigns-genmab-a-s-final-bb-rating-outlook-stable-03-02-2026
-
Amgen (AMGN) Q4 2025 Earnings Call Transcript https://www.theglobeandmail.com/investing/markets/stocks/AMGN/pressreleases/6356/amgen-amgn-q4-2025-earnings-call-transcript/ TEPEZZA grew 3% to $1.9 billion in '25 driven by higher net selling price.
Over 25,000 patients have received treatment since launch in The U.S. With growing interest from both new and returning prescribers. We continue to see increased prescribing by endocrinologists and a broadening base of specialists.
-
In Japan, approximately 1,200 patients have been treated since launch, reflecting growing awareness of the burden of thyroid eye disease among both patients and prescribers. We plan to launch TEPEZZA in additional markets in 2026, expanding access to this important therapy globally.
-
our international launches, our launch in Japan has gone extremely well. We're seeing nice uptake there. We're seeing a very well-received product for higher clinical activities for patients, and we're in the process of launching in multiple markets around the world as we speak. So overall, TEPEZZA will be a good growth driver for us this year.
-
AbbVie Q4 2025 Epkinlyc
US
21Internat
48Total
69 https://news.abbvie.com/2025-10-31-AbbVie-Reports-Third-Quarter-2025-Financial-Results -
2nd try: AbbVie Q4 2025 Epkinlyc US 22 Internat 59 Total 81 // Full year 86,
185, -
Another New Trial: Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors https://clinicaltrials.gov/study/NCT07387068
-
Novartis AG (NYSE:NVS) Q4 2025 Earnings Call Transcript https://www.insidermonkey.com/blog/novartis-ag-nysenvs-q4-2025-earnings-call-transcript-1689424/ Kesimpta grew 36% to $4.4 billion on the year. You can see the continued steady performance of this brand, driven by the continued expansion of the B-cell class within MS. In the U.S., we had 27% growth in quarter 4.
-
Importantly, we see increasing adoption in naive patients, which are now 50% of our NBRx is now in first line. Outside of the U.S., we are leading now with NBRx share in 9 out of the 10 of the major markets that we track. And the core opportunity we see ex U.S. going forward is to continue to expand B-cell therapies in the 67% of patients who are not on B-cell therapies and receiving disease-modifying therapies in MS.
-
Skulle regnskab ikke komme idag kl 17 ? Kommer det efter kl 22?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind